Suppr超能文献

支持 10-甲酰基二氢叶酸是体内氨基咪唑甲酰胺核苷酸转甲酰基酶的底物这一假说的证据。

Evidence for the hypothesis that 10-formyldihydrofolate is the in vivo substrate for aminoimidazolecarboxamide ribotide transformylase.

机构信息

Department of Nutrition Sciences, University of Alabama at Birmingham, 35294, USA.

出版信息

Exp Biol Med (Maywood). 2010 Mar;235(3):271-7. doi: 10.1258/ebm.2009.009151.

Abstract

We postulate that 10-formyl-7,8-dihydrofolate (10-HCO-H(2)folate), not 10-formyl-5,6,7,8-tetrahydrofolate (10-HCO-H(4)folate), is the predominant in vivo substrate for mammalian aminoimidazolecarboxamide ribotide (AICAR) transformylase, an enzyme in purine nucleotide biosynthesis de novo, which introduces carbon 2 (C(2)) into the purine ring. 10-HCO-H(2)folate exists in vivo as labeled 10-formyl-folic acid (10-HCO-folic acid: an oxidation product of 10-HCO-H(4)folate and 10-HCO-H(2)folate) and is found after doses of labeled folic acid in humans or laboratory animals. The bioactivity of the unnatural isomer, [6R]-5-formyltetrahydrofolate, in humans is explained by its in vivo conversion to 10-HCO-H(2)folate. The structure and active site of AICAR transformylase are not consistent with other enzymes that utilize 10-HCO-H(4)folate. Because 10-HCO-H(4)folate is rapidly oxidized in vitro to 10-HCO-H(2)folate by cytochrome C alone and in mitochondria, it is hypothesized that this process takes place in vivo. In vitro data indicate that 10-HCO-H(2)folate is kinetically preferred over 10-HCO-H(4)folate by AICAR transformylase and that this enzyme may not have access to sufficient supplies of 10-HCO-H(4)folate. Methotrexate blockage of the AICAR transformylase process in patients with rheumatoid arthritis suggests that dihydrofolate (H(2)folate) reductase is involved and is consistent with H(2)folate and 10-HCO-H(2)folate being the product and substrate for AICAR transformylase. The labeling of purine C(2) by an oral dose of [6RS]-5-H[(13)C]O-H(4)folate in a human subject is consistent with 10-H[(13)C]O-H(2)folate formation from unnatural isomer, [6R]-5-H[(13)C]O-H(4)folate, and it being a substrate for AICAR transformylase. In vitro exchange reactions of purine C(2) using H(4)folate coenzymes are not duplicated in vivo and is consistent with H(2)folate coenzymes being used in vivo by AICAR transformylase.

摘要

我们假设 10-甲酰基-7,8-二氢叶酸(10-HCO-H(2)叶酸),而不是 10-甲酰基-5,6,7,8-四氢叶酸(10-HCO-H(4)叶酸),是哺乳动物氨基咪唑甲酰胺核苷酸(AICAR)转甲酰基酶的主要体内底物,该酶是从头合成嘌呤核苷酸中的一种酶,它将碳 2(C(2))引入嘌呤环。10-HCO-H(2)叶酸在体内以标记的 10-甲酰基叶酸(10-HCO-叶酸:10-HCO-H(4)叶酸和 10-HCO-H(2)叶酸的氧化产物)的形式存在,并在人类或实验动物给予标记的叶酸后发现。在人类中,[6R]-5-甲酰基四氢叶酸这种非天然异构体的生物活性可通过其在体内转化为 10-HCO-H(2)叶酸来解释。AICAR 转甲酰基酶的结构和活性部位与利用 10-HCO-H(4)叶酸的其他酶不一致。由于 10-HCO-H(4)叶酸在体外可单独由细胞色素 C 和线粒体迅速氧化为 10-HCO-H(2)叶酸,因此推测该过程发生在体内。体外数据表明,AICAR 转甲酰基酶对 10-HCO-H(2)叶酸的动力学偏好高于 10-HCO-H(4)叶酸,并且该酶可能无法获得足够的 10-HCO-H(4)叶酸供应。甲氨蝶呤阻断类风湿关节炎患者的 AICAR 转甲酰基酶过程表明二氢叶酸(H(2)叶酸)还原酶参与其中,并且 H(2)叶酸和 10-HCO-H(2)叶酸是 AICAR 转甲酰基酶的产物和底物。在人类受试者中口服[6RS]-5-H[(13)C]O-H(4)叶酸后嘌呤 C(2)的标记与非天然异构体[6R]-5-H[(13)C]O-H(4)叶酸形成 10-H[(13)C]O-H(2)叶酸以及其作为 AICAR 转甲酰基酶的底物相一致。使用 H(4)叶酸辅酶的嘌呤 C(2)的体外交换反应在体内无法复制,并且与 AICAR 转甲酰基酶在体内使用 H(2)叶酸辅酶一致。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验